AstraZeneca: invests $2.5bn in R&D centre in Beijing
(CercleFinance.com) - AstraZeneca has announced a $2.
5bn investment in Beijing to establish its sixth global strategic R&D centre, the second in China, after Shanghai.
This project is part of a strategic partnership with the Beijing Municipal Government and the Beijing Economic and Technological Development Zone Administration.
The five-year investment includes research agreements with biotechs Harbour BioMed, Syneron Bio and BioKangtai.
The R&D centre will be located in Beijing's BioPark, close to biotechs and research hospitals. AstraZeneca also plans to create 1,700 jobs in Beijing.
Copyright (c) 2025 CercleFinance.com. All rights reserved.
5bn investment in Beijing to establish its sixth global strategic R&D centre, the second in China, after Shanghai.
This project is part of a strategic partnership with the Beijing Municipal Government and the Beijing Economic and Technological Development Zone Administration.
The five-year investment includes research agreements with biotechs Harbour BioMed, Syneron Bio and BioKangtai.
The R&D centre will be located in Beijing's BioPark, close to biotechs and research hospitals. AstraZeneca also plans to create 1,700 jobs in Beijing.
Copyright (c) 2025 CercleFinance.com. All rights reserved.